ReviewFrontiers in immunology2023
Potential angiogenic, immunomodulatory, and antifibrotic effects of mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials.Stem cell research & therapy · 2025Pooled it
- Plasma-Derived Extracellular Vesicle-Enriched Fractions as a Potential Source of Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): A Shotgun Proteomic Exploration Analysis.Diagnostics (Basel, Switzerland) · 2026Article
- The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis.Reumatologia · 2026Review
- Priming strategies to enhance the therapeutic efficacy of mesenchymal stromal/stem cell-derived vesicles in regenerative medicine.Extracellular vesicles and circulating nucleic acids · 2026Review
- Epigenetic memory as a readout of environmental susceptibility defines cell manufacturability in mesenchymal stem cell production.Stem cell research & therapy · 2025Article
- miR29a-Loaded Extracellular Vesicles Derived from Human Mesenchymal Stem Cells Inhibit Fibrotic and Inflammatory Signaling.ACS omega · 2025Article
- Review
- Fibrotic Disease of the Skin and Lung: Shared Pathways, Environmental Drivers, and Therapeutic Opportunities in a Changing Climate.International journal of molecular sciences · 2025Review
- Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases.Immunity, inflammation and disease · 2025Review
- Validity and psychometric characteristics of the Duruöz Hand Index (DHI) with systemic sclerosis.Rheumatology international · 2025Article
- The Potential Application of Exosomes as Therapeutic Agents, Carriers, and Biomarkers in Skin Diseases.International journal of nanomedicine · 2025Review
- Optimizing mesenchymal stem cell extracellular vesicles for chronic wound healing: Bioengineering, standardization, and safety.Regenerative therapy · 2024Review
- Astragalus polysaccharides augment BMSC homing via SDF-1/CXCR4 modulation: a novel approach to counteract peritoneal mesenchymal transformation and fibrosis.BMC complementary medicine and therapies · 2024Article
- Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment.Frontiers in medicine · 2024Review
- Mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis: role and therapeutic directions.Frontiers in cell and developmental biology · 2024Review
- Associations of the circulating levels of cytokines with risk of systemic sclerosis: a bidirectional Mendelian randomized study.Frontiers in immunology · 2024Article
- Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review.Biomedicines · 2023Review
- The role of inflammation in autoimmune disease: a therapeutic target.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is an intricate systemic autoimmune disease with pathological features such as vascular injury, immune dysregulation, and extensive fibrosis of the skin and multiple organs. Treatment options are limited; however, recently, mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have been acknowledged in preclinical and clinical trials as being useful in treating autoimmune diseases and are likely superior to MSCs alone. Recent research has also shown that MSC-EVs can ameliorate SSc and the pathological changes in vasculopathy, immune dysfunction, and fibrosis. This review summarizes the therapeutic effects of MSC-EVs on SSc and the mechanisms that have been discovered to provide a theoretical basis for future studies on the role of MSC-EVs in treating SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.